These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19947907)

  • 1. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers.
    Harb G; Lebel F; Battikha J; Thackara JW
    Curr Med Res Opin; 2010 Feb; 26(2):279-88. PubMed ID: 19947907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
    Dychter SS; Harrigan R; Bahn JD; Printz MA; Sugarman BJ; DeNoia E; Haughey DB; Fellows D; Maneval DC
    Clin Ther; 2014 Feb; 36(2):211-24. PubMed ID: 24486335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers.
    Thomas JR; Yocum RC; Haller MF; Flament J
    J Pain Symptom Manage; 2009 Nov; 38(5):673-82. PubMed ID: 19819667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness.
    Thomas JR; Wallace MS; Yocum RC; Vaughn DE; Haller MF; Flament J
    J Pain Symptom Manage; 2009 Nov; 38(5):663-72. PubMed ID: 19819665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion.
    Vaughn DE; Muchmore DB
    Endocr Pract; 2011; 17(6):914-21. PubMed ID: 22138081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized clinical trial of recombinant human hyaluronidase-facilitated subcutaneous versus intravenous rehydration in mild to moderately dehydrated children in the emergency department.
    Spandorfer PR; Mace SE; Okada PJ; Simon HK; Allen CH; Spiro DM; Friend K; Harb G; Lebel F;
    Clin Ther; 2012 Nov; 34(11):2232-45. PubMed ID: 23062548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase.
    Muchmore DB; Vaughn DE
    J Diabetes Sci Technol; 2012 Jul; 6(4):764-72. PubMed ID: 22920800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
    Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
    Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers.
    Dolton MJ; Chesterman A; Moein A; Sink KM; Waitz A; Blondeau K; Kerchner GA; Hu N; Brooks L; Wetzel-Smith MK; Roden A; Deshmukh A; Peng K; Carrasco-Triguero M; Smith J; Ostrowitzki S; Quartino A
    Clin Pharmacol Ther; 2021 Nov; 110(5):1337-1348. PubMed ID: 34347883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
    Wasserman RL; Melamed I; Stein MR; Engl W; Sharkhawy M; Leibl H; Puck J; Rubinstein A; Kobrynski L; Gupta S; Grant AJ; Ratnayake A; Richmond WG; Church J; Yel L; Gelmont D
    J Clin Immunol; 2016 Aug; 36(6):571-82. PubMed ID: 27220317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase.
    Vaughn DE; Yocum RC; Muchmore DB; Sugarman BJ; Vick AM; Bilinsky IP; Frost GI
    Diabetes Technol Ther; 2009 Jun; 11(6):345-52. PubMed ID: 19459762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20.
    Morcos PN; Zhang X; McIntyre C; Bittner B; Rowell L; Hussain Z
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):537-48. PubMed ID: 23547849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.
    Morrow L; Muchmore DB; Ludington EA; Vaughn DE; Hompesch M
    Diabetes Technol Ther; 2011 Oct; 13(10):1039-45. PubMed ID: 21714645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer.
    Kang DW; Bittner B; Sugarman BJ; Zepeda ML; Printz MA
    PLoS One; 2021; 16(7):e0254765. PubMed ID: 34292990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema.
    Riedl MA; Lumry WR; Li HH; Banerji A; Bernstein JA; Ba M; Bjrkander J; Magerl M; Maurer M; Rockich K; Chen H; Schranz J
    Allergy Asthma Proc; 2016 Nov; 37(6):489-500. PubMed ID: 27931305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous Injection Performance in Yucatan Miniature Pigs with and without Human Hyaluronidase and Auto-injector Tolerability in Humans.
    Shi GH; Connor RJ; Collins DS; Kang DW
    AAPS PharmSciTech; 2021 Jan; 22(1):39. PubMed ID: 33409604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats.
    Styles IK; Feeney OM; Nguyen TH; Brundel DHS; Kang DW; Clift R; McIntosh MP; Porter CJH
    J Control Release; 2019 Dec; 315():85-96. PubMed ID: 31655131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated ringer's solution administered subcutaneously: A phase IV, double-blind, randomized pilot study in healthy volunteers.
    Dychter SS; Ebel D; Mead TR; Yocum RC
    Curr Ther Res Clin Exp; 2009 Dec; 70(6):421-38. PubMed ID: 24692835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study.
    Thomas JR; Yocum RC; Haller MF; von Gunten CF
    J Palliat Med; 2007 Dec; 10(6):1312-20. PubMed ID: 18095810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase.
    Shpilberg O; Jackisch C
    Br J Cancer; 2013 Sep; 109(6):1556-61. PubMed ID: 24002601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.